GlyCardial Diagnostics have received €1.9 million of the SME Instrument phase II funding, in the framework of H2020 programme, to advance in the development of its novel test for the early detection of cardiac ischemia.

"So amazing to have it approved in our first trial. It is highly motivating to see that the EU trusts in our project as much as we do" says Dr Judit Cubedo, CEO at Glycardial.

Founded in 2017 by Prof Lina Badimon, Dr Judit Cubedo, Dr Teresa Padró and Dr Gemma Vilahur, Glycardial is a spin-off of the Research Institute of the Hospital de la Santa Creu i Sant Pau in Barcelona. Glycardial is a CataloniaBio & HealthTech member.

We recommend this video of CataloniaBio & HealthTech interviewing Judit Cubedo: